Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
BACKGROUND: Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a ph...
Main Authors: | Keymeulen, B, Vandemeulebroucke, E, Ziegler, A, Mathieu, C, Kaufman, L, Hale, G, Gorus, F, Goldman, M, Walter, M, Candon, S, Schandene, L, Crenier, L, De Block, C, Seigneurin, J, De Pauw, P, Pierard, D, Weets, I, Rebello, P, Bird, P, Berrie, E, Frewin, M, Waldmann, H, Bach, J, Pipeleers, D, Chatenoud, L |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
by: Keymeulen, B, et al.
Published: (2010) -
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
by: Keymeulen, B, et al.
Published: (2010) -
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
by: Hale, G, et al.
Published: (2010) -
Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
by: Alkemade, G, et al.
Published: (2011) -
Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.
by: Annelien Van Dalem, et al.
Published: (2016-01-01)